Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pediatrix Medical (MD) EBITDA (2016 - 2026)

Pediatrix Medical (MD) has disclosed EBITDA for 17 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 14.28% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.1 million through Dec 2025, up 270.61% year-over-year, with the annual reading at $167.1 million for FY2025, 270.61% up from the prior year.
  • EBITDA for Q4 2025 was $33.8 million at Pediatrix Medical, down from $72.0 million in the prior quarter.
  • The five-year high for EBITDA was $72.0 million in Q3 2025, with the low at -$152.8 million in Q2 2024.
  • Average EBITDA over 5 years is $13.7 million, with a median of $27.0 million recorded in 2021.
  • The sharpest move saw EBITDA tumbled 647.86% in 2024, then skyrocketed 425.42% in 2025.
  • Over 5 years, EBITDA stood at $68.0 million in 2021, then crashed by 55.85% to $30.0 million in 2022, then tumbled by 509.61% to -$123.0 million in 2023, then soared by 124.08% to $29.6 million in 2024, then rose by 14.28% to $33.8 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $33.8 million, $72.0 million, and $39.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.